SK bioscience has made a large-scale investment of about KRW 500 billion to establish production and R&D infrastructure, recognizing that the global life science paradigm is shifting from ‘treatment’ to ‘prevention’. Over the past years, it also has developed and acquired various vaccine production technologies and platforms for capacity building. Based on this, SK bioscience conducts vaccine business across the entire value chain across R&D, production, distribution, and sales.
Company Information
| Organization | Language | SK bioscience Co., Ltd. |
|---|---|---|
| Company name | English | SK bioscience Co., Ltd. |
| Korean | 에스케이바이오사이언스 주식회사 | |
| Activity and key brands, products and services | R&D, production, and sales of vaccines and biopharmaceuticals | |
| Headquarters | 310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea | |
| Business region | 150, Saneopdanji-gil, Pungsan-eup, Andong-si, Gyeongsangbuk-do, Republic of Korea | |
Business Introduction
<Business Model>
Pipeline
Based on its successful experience of developing and commercializing four vaccine products, SK bioscience has been focusing on the development of vaccines with high potential to lead the future vaccine industry.
We attempt to expand our vaccine product portfolios by developing and acquiring various pipeline ranging from basic vaccines such as typhoid conjugate vaccine to premium vaccines which include the next-generation pneumococcal conjugate vaccine and RSV vaccine. In addition, we fortify our position through joint vaccine development and collaborations with multinational companies, international organizations, and biotechnology companies based on our R&D capability.
SK bioscience has developed a COVID-19 vaccine based on accumulated experience and technology of vaccine development. SKYCovione, which was developed with the funding from Bill & Melinda Gates Foundation(BMGF) and Coalition for Epidemic Preparedness Innovations(CEPI), was the first domestic COVID-19 vaccine to receive approval from the Ministry of Food and Drug Safety on June 29, 2022.
Our attempts to address the global public health needs do not stop with the development of the COVID-19 vaccine. By developing vaccines that can prepare us for the next pandemic, such as a Universal Coronavirus(Sarbecovirus) vaccine, we aim to contribute to public health protection.
<Pipeline>
Commercialization of In-house-developed Vaccines
<Developed Vaccines>
COVID-19 Vaccine Business in 2021
SK bioscience has generated business performance by implementing a ‘Two-track’ strategy for the stable supply of COVID-19 vaccine in Korea.
<Two-Track Strategy>
Other Domestic Business and Global Partnerships
SK bioscience’s domestic business consists of joint sales, C(D)MO (insourcing and outsourcing). It leads the domestic vaccine market by cooperating with domestic and overseas major pharmaceutical companies in the form C(D)MO. We conduct joint research and development with overseas leading partners and institutions and carry out technology transfers and production based on high manufacturing capacity.